[HTML][HTML] Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments

L Zuo, ER Prather, M Stetskiv, DE Garrison… - International journal of …, 2019 - mdpi.com
It has been proposed that a chronic state of inflammation correlated with aging known as
inflammaging, is implicated in multiple disease states commonly observed in the elderly …

PI3K/Akt/mTOR signaling pathway as a target for colorectal cancer treatment

PD Leiphrakpam, C Are - International journal of molecular sciences, 2024 - mdpi.com
In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer
(CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed …

Signaling pathways in inflammation and anti-inflammatory therapies

YT Yeung, F Aziz, A Guerrero-Castilla… - Current …, 2018 - ingentaconnect.com
During the past decade, an abundance of new evidence highlighted the importance of
inflammation in the development of chronic pathologies such as neurodegeneration, cancer …

Targeting PI3K/Akt/mTOR signaling in cancer

C Porta, C Paglino, A Mosca - Frontiers in oncology, 2014 - frontiersin.org
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and …

[HTML][HTML] Targeting PI3K/AKT/mTOR signaling pathway in breast cancer

H Li, L Prever, E Hirsch, F Gulluni - Cancers, 2021 - mdpi.com
Simple Summary PI3K signaling pathway plays an essential role in many cellular processes
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …

[HTML][HTML] PI3K inhibitors in inflammation, autoimmunity and cancer

AK Stark, S Sriskantharajah, EM Hessel… - Current opinion in …, 2015 - Elsevier
Highlights•Preclinical studies support us of PI3K inhibitors in autoimmunity and
inflammation.•First in class PI3K inhibitor has been approved for treatment of B cell …

PI3K/AKT/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: Crosstalk with the VHL/HIF axis

SC Badoiu, M Greabu, D Miricescu… - International journal of …, 2023 - mdpi.com
Renal cell carcinoma (RCC) represents 85–95% of kidney cancers and is the most frequent
type of renal cancer in adult patients. It accounts for 3% of all cancer cases and is in 7th …

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

A Akinleye, P Avvaru, M Furqan, Y Song… - Journal of hematology & …, 2013 - Springer
Abstract Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse
cellular processes including proliferation, adhesion, survival, and motility. Dysregulated …

Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy

EE Stratikopoulos, M Dendy, M Szabolcs, AJ Khaykin… - Cancer cell, 2015 - cell.com
Unsustained enzyme inhibition is a barrier to targeted therapy for cancer. Here, resistance to
a class I PI3K inhibitor in a model of metastatic breast cancer driven by PI3K and MYC was …

Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy

X Yu, YC Long, HM Shen - Autophagy, 2015 - Taylor & Francis
Autophagy is an evolutionarily conserved and exquisitely regulated self-eating cellular
process with important biological functions. Phosphatidylinositol 3-kinases (PtdIns3Ks) and …